Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone/Formoterol BAI vs Relvar Ellipta in Asthma
NCT02753712Phase 3Completed
- Sponsor
- Mundipharma
- Start
- Jun 2016
- Primary completion
- Aug 2017
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 3, randomised, single-blind trial of fluticasone propionate + formoterol in asthma (2 arms), sponsored by Mundipharma. Primary endpoint: Peripheral Airway Resistance at 8 weeks. Started Jun 2016; status: completed.
02
Drugs
fluticasone propionate + formoterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02753712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753712.